Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

Race Oncology (ASX:RAC) has started working with George Clinical under a work order (WO) agreement for its Phase 1 RAC-010 ...

VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025 ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical ...

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...